Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

Publisher： Karger

E-ISSN： 2296-5262|26|4|351-354

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.26, Iss.4, 2003-09, pp. : 351-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

Results of Treatment with Rituximab (Anti-CD20) in Three Patients with Autoimmune Hemolytic Anemia and/or Immune Thrombocytopenia and a Concise Review of Reported Cases

By  

Transfusion Medicine and Hemotherapy, Vol. 29, Iss. 5, 2002-10 ,pp. : 277-281

Karger

Access to resources Recommend Favorite

Effective Treatment of Refractory Pulmonary Hemorrhage with Monoclonal Anti-CD20 Antibody (Rituximab)

By  

Respiration, Vol. 78, Iss. 1, 2008-09 ,pp. : 106-109

Karger

Access to resources Recommend Favorite

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

By  

Case Reports in Oncology, Vol. 2, Iss. 3, 2009-10 ,pp. : 194-202

Karger

Access to resources Recommend Favorite